Dr. Chen leads the MGH Blood and Marrow Transplant center. He divides his time between patient care, clinical research and program administration with a focus on patients undergoing bone marrow/stem cell transplantation. His clinical interests include: Bone marrow, Stem cell, Cord blood transplant, Acute and chronic leukemia, Hodgkin’s and Non-Hodgkin’s lymphoma, Multiple myeloma, Aplastic anemia, and

Myelodysplastic syndrome (MDS).

Yi-Bin Chen grew up in New Jersey. He majored in molecular biophysics and biochemistry, earning a B.S./M.S. at Yale University before attending medical school at Harvard Medical School. Subsequently, he did his internship and residency at Massachusetts General Hospital including an additional year as Chief Resident. This was followed by a fellowship in hematology / oncology at the Dana-Farber Partners combined program. In 2008, he joined the staff of the Blood & Marrow Transplant (BMT) Program at the MGH Cancer Center, has served as Director of Clinical Research since 2012 and was named overall Program Director in 2016. His interests mainly revolve around improving the outcomes of patients undergoing autologous and allogeneic stem cell transplantation. He has led original clinical trials involving all aspects of BMT including conditioning regimens, alternative graft sources, novel approaches concerning the prevention and therapy of acute and chronic graft-vs-host disease (GVHD) and the use of maintenance therapies after BMT. He collaborates extensively with local and national colleagues as well as industry in addition to developing his own original clinical trials.

Dr. Chen completed his medical degree MD at Harvard Medical School; Residency at Massachusetts General Hospital; and his Fellowship at Dana Farber Cancer Institute. He is Board Certified in Medical Oncology.